PPARγ-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 5, 1999, Pages 798-806

  Goetze, Stephan ^a,b   Xi, Xiao Ping ^a   Kawano, Hiroaki ^a   Gotlibowski, Tina ^a   Fleck, Eckart ^b   Hsueh, Willa A ^a   Law, Ronald E ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

MAPK; Migration; PPAR ; Vascular smooth muscle cells

Indexed keywords

15 DEOXY DELTA PROSTAGLANDIN J2; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; DACTINOMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN J2; ROSIGLITAZONE; SOMATOMEDIN C; THROMBIN; TROGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL CELL; AORTA; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE;

ANIMALS; AORTA, THORACIC; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL MOVEMENT; CELLS, CULTURED; CHEMOTACTIC FACTORS; CHROMANS; CYCLOHEXIMIDE; DACTINOMYCIN; ENZYME ACTIVATION; INSULIN-LIKE GROWTH FACTOR I; LIGANDS; MUSCLE, SMOOTH, VASCULAR; PLATELET-DERIVED GROWTH FACTOR; PROSTAGLANDIN D2; PROTEIN SYNTHESIS INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; THROMBIN; TRANSCRIPTION FACTORS;

EID: 0032890834     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199905000-00018     Document Type: Article

References (56)

1. Schwartz SM. Perspectives series: cell adhesion in vascular biology: smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997;99:2814-6.
2. Abedi H, Zachary I. Signalling mechanisms in the regulation of vascular cell migration. Cardiovasc Res 1995;30:544-56.
3. Graf K, Xi XP, Yang D, Fleck E, Hsueh WA, Law RE. Mitogen-activated protein kinase activation is involved in platelet-derived growth factor-directed migration by vascular smooth muscle cells. Hypertension 1997;29(1 Pt 2):334-9.
4. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimai hyperplasia. J Clin Invest 1996;98:1897-905.
5. Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC. Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein kinase. J Vasc Surg 1998;27:117-25.
6. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-92.
7. Morrison DL, Sanghera JS, Stewart J, Sutherland C, Walsh MP, Pelech SL. Phosphorylation and activation of smooth muscle myosin light chain kinase by MAP kinase and cyclin-dependent kinase-1. Biochem Cell Biol 1996;74:549-57.
8. Garcia JGN, Verin AD, Herenyiova M, English D. Adherent neutrophils activate endothelial myosin light chain kinase: role in transendothelial migration. J Appl Physiol 1998;84:1817-21.
9. Pauly RR, Bilato C, Sollott SJ, et al. Role of calcium/calmodulin-dependent protein kinase II in the regulation of vascular smooth muscle cell migration. Circulation 1995;91:1107-15.
10. Bilato C, Pauly RR, Melillo G, et al. Intracellular signaling pathways required for rat vascular smooth muscle cell migration: interactions between basic fibroblast growth factor and platelet-derived growth factor. J Clin Invest 1995;96:1905-15.
11. Bornfeldt KE, Raines EW, Nakano T, Graves LM, Krebs EG, Ross R. Insulin-like growth factor-I and platelet-derived growth factor-BB induce directed migration of human arterial smooth muscle cells via signaling pathways that are distinct from those of proliferation. J Clin Invest 1994;93:1266-74.
12. Fukui R, Shibata N, Kohbayashi E, et al. Inhibition of smooth muscle cell migration by the p21 cyclin-dependent kinase inhibitor (Cip1). Atherosclerosis 1997;132:53-9.
13. Zhu NL, Wu L, Liu PX, et al. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997;96:628-35.
14. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:14553-6.
15. Gille H, Kortenjann M, Thomae O, et al. ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995;14:951-62.
16. Gille H, Kortenjann M, Strahl T, Shaw PE. Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE. Mol Cell Biol 1996;16:1094-102.
17. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995;83: 803-12.
18. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998;47:507-14.
19. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
20. Mukherjee R, Davies PJ, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997;386:407-10.
21. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
22. Tonlonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
23. Vidal-Puig A, Jimenez-Linan M, Lowell BB, et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996;97:2553-61.
24. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996;137:354-66.
25. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 1996;222:844-51.
26. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
27. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998;1:465-70.
28. Iijima K, Yoshizumi M, Ako J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells. Biochem Biophys Res Commun 1998;247: 353-6.
29. Law RE, Xi XP, Goetze S, Meehan WP, Hsueh WA. Expression and function of PPARgamma/RXRalpha in VSMC and during intimal hyperplasia [Abstract]. Circulation 1998;98:1-182.
30. Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol 1995;268(5 Pt 1):C1195-201.
31. Gockerman A, Prevette T, Jones JI, Clemmons DR. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology 1995; 136:4168-73.
32. Jones JI, Prevette T, Gockerman A, Clemmons DR. Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc Natl Acad Sci USA 1996;93:2482-7.
33. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev 1979;59:1-61.
34. Casscells W. Migration of smooth muscle and endothelial cells: critical events in restenosis. Circulation 1992;86:723-9.
35. Raines EW, Ross R. Multiple growth factors are associated with lesions of atherosclerosis: specificity or redundancy? Bioessays 1996;18:271-82.
36. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996;16:28-33.
37. Grotendorst GR, Seppa HE, Kleinman HK, Martin GR. Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci USA 1981;78: 3669-72.
38. Ferns GA, Raines EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 1991;253:1129-32.
39. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D. Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988;82: 1134-43.
40. Zucker S, Conner C, DiMassmo BI, et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells: physiologic regulation of angiogenesis. J Biol Chem 1995;270:23730-8.
41. Galis ZS, Kranzhofer R, Fenton JW II, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:483-9.
42. Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res 1990;66:1755-60.
43. Sobieszek A. Calmodulin-dependent autophosphorylation of smooth muscle myosin light chain kinase: intermolecular reaction mechanism via dimerization of the kinase and potentiation of the catalytic activity following activation. Biochemistry 1995;34: 11855-63.
44. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 1995;83:813-9.
45. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not by PPAR-gamma activators. Nature 1998;393:790-3.
46. Young PW, Buckle DR, Cantello BC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther 1998;284:751-9.
47. Yang-Yen HF, Chambard JC, Sun YL, et al. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990;62:1205-15.
48. Chen JY, Penco S, Ostrowski J, et al. RAR-specific agonist/ antagonists which dissociate transactivation and API transrepression inhibit anchorage-independent cell proliferation. EMBO J 1995;14:1187-97.
49. Fanjul A, Dawson MI, Hobbs PD, et al. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994;372:107-11.
50. Hultgardh-Nilsson A, Cercek B, Wang JW, et al. Regulated expression of the ets-1 transcription factor in vascular smooth muscle cells in vivo and in vitro. Circ Res 1996;78:589-95.
51. Newberry EP, Willis D, Latifi T, Boudreaux JM, Towler DA. Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element. Mol Endocrinol 1997;11:1129-44.
52. Anglard P, Melot T, Guerin E, Thomas G, Basset P. Structure and promoter characterization of the human stromelysin-3 gene. J Biol Chem 1995;270:20337-44.
53. Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes 1995;44:369-74.
54. Willson TM, Cobb JE, Cowan DJ, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996;39:665-8.
55. Minamikawa J, Tanaka S, Yamaucht M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83: 1818-20.
56. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-94.